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The amount of glucose in the blood measured in mmo1L·1. In 
people with out diabetes blood glucose levels are below 6 
mmo1L·1. People with diabetes are encouraged to monitor 
their blood glucose levels regularly usually, by afingerprick 
test. 
A group of metabolic disorders in which glucose metabolism 
is abnormal. 
Fear of hypoglycaemia An anxiety disorder, specific to people with diabetes, in 
which people have a phobic avoidance of hypoglycaemia. 
Finger prick test A self-administered test for blood glucose levels, which 
involves pricking a finger to obtain a small amount of blood 
to be analysed in a blood glucose machine. 
HbA1c - glycated haemoglobin The clinically recommended index of metabolic 
Hyperglycaemia 
control over the previous six to eight weeks. See also 
metabolic control. 
A condition in which the blood glucose level is higher than 
normal (approximately above 7 mmo1"1). See also metabolic 
control. 
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describe people with early onset type 1 diabetes which 
sometimes includes people with type 2 diabetes that are on 
insulin therapy. 
A hormone produced by the pancreas that acts to regulate 
blood glucose levels. Synthetic or animal insulin is 
prescribed for all people with type 1 and people with more 
advanced type 2 diabetes. 
A condition in which blood glucose levels are lower than 
normal (Approximately below 3 mmolL"1). See also 
metabolic control. 
People are advised to keep blood glucose levels between 3 
and 7 mmo1L·1. Above this range people become more likely 
to experience diabetes-related complications associated with 
hyperglycaemia such as retinopathy, peripheral neuropathy, 
and nephropathy. Below this range (hypogzycaemia) there is 
a risk of coma and in severe cases, death. 
An oral anti-diabetic agent that acts to reduce peripheral 
insulin resistance resulting in lower blood glucose levels. 
Metformin does not cause hypoglycaemia in therapeutic 
doses. 
Vll 
Non-Insulin Dependent Diabetes Mellitus (NIDDM) A common usage term to 
Sulphonylureas 
Type 1 diabetes 
Type 2 diabetes 
describe people with type 2 diabetes. 
Oral anti-diabetic agents that act by stimulating insulin 
release from the pancreas. Four varieties are available in 
New Zealand; glibenclamide, gliclazide, glipizide and 
tolbutamide. All sulphonylureas can cause hypoglycaemia. 
A form of diabetes in which the pancreas does not produce 
insulin, resulting in a dependence on regular insulin injections 
for survival. Type 1 diabetes is generally diagnosed in 
infancy through to young adulthood and the majority of cases 
have a genetic marker present. 
The most common form of diabetes, caused by a resistance 
and/or a deficit in insulin secretion by the pancreas. It is 
usually diagnosed in adulthood and is generally caused by 
lifestyle factors such as diet, weight and lack of exercise. 
LIST OF ABBREVIATIONS 
Diabetes related terms: 
IDDM 
NIDDM 
Indulin dependent diabetes mellitus 










Fear of hypoglycaemia is an anxiety disorder that is specific to people with diabetes. 
People with a fear of hypoglycaemia (low blood sugar) typically modify their 
behaviour (a phobic response) to avoid low blood glucose levels in order to reduce 
their anxiety. By avoiding the feared situation, the maladaptive avoidance behaviour 
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is negatively reinforced. However, people that keep their blood sugars high are at risk 
of serious diabetes-related complications. This study investigated the prevalence of 
fear of hypoglycaemia in people attending the Christchurch Diabetes Centre and 
considered which factors influence the development and maintenance of fear of 
hypoglycaemia. It was found that 18% of patients surveyed had a high fear of 
hypoglycaemia and that in some cases, metabolic control was likely to be 
compromised. Anxiety and previous experience of hypoglycaemia were the factors 
that were the most strongly liked to fear of hypoglycaemia. 
1. INTRODUCTION 
This study was initiated to clarify the anecdotal evidence of diabetes physicians 
that there appeared to be an association between fear of hypoglycaemia and higher 
blood glucose levels in patients attending the Christchurch Diabetes Clinic (Joss 
Tennent, personal communication). Fear of hypoglycaemia is still relatively little 
studied and there have been no studies published investigating fear of 
hypoglycaemia in New Zealanders with diabetes. 
1.1. Overview of diabetes 
1.1.1. Physiology of diabetes 
Diabetes mellitus is not a single disease but is a group of metabolic disorders in 
which glucose metabolism is abnormal (The Expert Committee on the Diagnosis 
and Classification of Diabetes Mellitus, 2002). Glucose metabolism in people 
without diabetes is homeostatic. When blood glucose levels rise above the normal 
range (between 4 and 8 mmol/L) insulin is automatically released from the 
pancreas. The insulin acts to reduce excess blood glucose in the blood stream by 
moving it into muscles (for short-term storage) and fat and liver cells (for long 
term storage). When glucose levels fall below normal the pancreas releases. 
glucagons, which act to release the stored glucose from fat and liver cells into the 
blood stream. In people with diabetes this automatic control of glucose is 
impaired either by an absence or deficiency in insulin release from the pancreas, 
or a resistance to insulin action that builds up over time. This results in 
uncontrolled rises in blood glucose (hyperglycaemia) to potentially harmful levels, 
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which is common to all types of diabetes. Symptoms of hyperglycaemia include 
polyuria (increased urination), excessive thirst, weight loss and blurred vision. 
Long-term complications of persistent hyperglycaemia include retinopathy with 
potential loss of sight, renal failure, peripheral neuropathy increasing the 
likelihood of ulcers and lower leg amputation, autonomic neuropathy resulting in 
gastrointestinal, genitourinary and cardiovascular problems, and sexual 
dysfunction. Therefore it is an important part of diabetes management to maintain 
blood glucose at levels low enough to avoid these potentially debilitating 
complications. 
1. 1. 2. Type 1 and Type 2 Diabetes 
The two most common forms of diabetes are known as Type 1 and Type 2. In 
Type 1 diabetes the pancreas does not produce insulin, and therefore these patients 
are dependent on insulin injections for survival. This form of diabetes is generally 
diagnosed in infancy through to young adulthood and the majority of cases have a 
genetic marker present. 
Type 2 is the most prevalent form of diabetes and accounts for 85-90% of all 
diabetes cases in developed countries (Ministry of Health, 1999). Type 2 diabetes 
is due to a resistance to insulin and or a deficit in insulin secretion. It is usually 
diagnosed in adulthood, becoming more common with age. This form of diabetes 
is often undiagnosed for a significant time before it becomes severe enough for 
the patient to seek treatment, often in response to stress or an illness [ECDCDM], 
2000 #75], however, in this time damage due to hyperglycaemia can have already 
occurred. 
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It should be noted that although type 1 and type 2 are the terms recommended by 
the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, 
(2002), there is common usage of the terms Insulin Dependent Diabetes Mellitus 
(IDDM) and Non-Insulin Dependent Diabetes Mellitus (NIDDM). Although 
IDDM is generally used to describe those with the earlier onset, genetically 
determined, type 1 diabetes it can sometimes include those with type 2 diabetes 
who are on insulin therapy. NIDDM is only used for patients with type 2 diabetes 
as all patients that have type 1 should be on insulin therapy. Therefore the cause 
of the diabetes is less clear when these terms are used. 
1.1.3. Diabetes in New Zealand 
As diabetes affects a large number of New Zealanders it has become a major focus 
for health authorities (Health Funding Authority, 2000). It is important for both 
financial and social reasons to limit the effect of this disease as much as possible. 
The New Zealand Health Survey (Sarfati & Scott, 2000) found that 1 in 27 New 
Zealanders has diabetes and that the prevalence is increasing rapidly (Simmons, 
Harry, & Gatland, 1999). Maori and Pacific Island People are twice as iikely as 
New Zealanders of European descent to have diabetes and it is expected to 
increase by 97% among Maori and 47% for New Zealanders of European descent 
over the next 20 years (Health Funding Authority, 2000). The increase in type 2 
diabetes has been attributed to an increase in the Polynesian population and in the 
number of elderly, however the smaller rise in type 1 diabetes is unexplained 
(Moore & Lunt, 2000). 
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In Maori and Pacific Island people type 1 accounts for 5% of all diabetes but this 
rises to 11 % in New Zealanders of European descent (Health Funding Authority, 
2000). The total number of New Zealanders with type 1 diabetes is estimated to 
be 10, 500. In the area serviced by the Canterbury District Health Board there is 
estimated to be almost four and a half thousand people with diabetes, with type 1 
diabetes more common in this region than the rest of New Zealand possibly due to 
a genetic cause (Health Funding Authority, 2000). 
1.1.4. Treatment of diabetes 
In mild to moderate cases, type 2 diabetes is managed by diet and other lifestyle 
changes including exercise, but as the disease progresses, medications to increase 
the body's sensitivity to insulin such as metformin, sulphonylurea drugs, and 
insulin may be prescribed (Garber, 1999). 
Metformin is an oral anti-diabetic agent (tablet form) that acts to reduce peripheral 
insulin resistance resulting in lowered blood glucose. Metformin is generally the 
agent of choice for patients with type 2 diabetes that are unable to control their 
blood glucose by diet alone. It is sometimes prescribed in conjunction with a 
sulphonylurea and or insulin. Metformin does not cause hypoglycaemia in 
therapeutic doses 
Sulphonylureas act by stimulating insulin release from the pancreas and are used 
to treat type 2 diabetes only. There are four types (tablets) available in New 
Zealand - glibenclamide, gliclazide, glipizide and tolbutamide. All 
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sulphonylureas can cause hypoglycaemia and patients prescribed these are 
instructed in hypoglycaemia management. 
Insulin is taken by all patients with type 1 diabetes and more advanced type 2 
diabetes. It is self-administered by injection between one and four times a day. 
Regular self-testing of blood glucose levels is required to maintain insulin levels 
at a therapeutic level. There are at least two kinds of insulin, synthetic and animal 
insulin, and many varieties with different profiles of insulin action. Therefore, 
insulin regimes are individualised to suit each patient. Some patients with type 2 
diabetes may take metformin and or a sulphonylurea in addition to insulin. 
Insulin causes hypoglycaemia when there has been insufficient food intake or 
excessive exercise for the insulin dose administered. 
1.1. 5. Hypoglycaemia 
An important side effect of sulphonylurea drugs and insulin therapy is the risk of 
hypoglycaemia. Hypoglycaemia occurs when blood glucose falls to a low level 
and it occurs by either an excess of insulin for the amount of food ingested or a 
level of physical activity that has used up available glucose. Symptoms of mild 
hypoglycaemia include shaking, sweating and a rapid heart rate and these can be 
quickly treated by administration of glucose, often in the form of special tablets or 
sweets such as jellybeans. In more severe hypoglycaemic episodes, glucose 
supply to the brain is reduced resulting in symptoms such as lethargy, mental 
slowing, and eventually coma and death ifleft untreated. Patients with severe 
hypoglycaemic episodes generally need assistance from others to administer 
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treatment, for example high sugar foods or in the most severe cases intravenous 
infusions of dextrose. 
Recurrent hypoglycaemia can have lasting negative effects on cognitive function 
including reduced ability to process new information, decreased speed of 
performance and decreased decision-making ability (Frier, 2001; Gold, Deary, & 
Frier, 1993). Almost all patients who are prescribed insulin experience mild 
hypoglycaemia at some time and many who take sulphonylurea drugs may also 
experience hypoglycaemia. As a general rule, patients begin to notice the early 
symptoms of hypoglycaemia when blood glucose levels are less than 3.0 mmol/1, 
however, this varies between individuals. 
Severe hypoglycaemia is more common in people with type 1 diabetes than type 2 
as those with type 2, even when on insulin or sulphonylurea drugs, generally have 
a more intact counter-regulatory response to low blood sugar levels (Gerich, 2000; 
Peacy, Robinson, & Bedford, 2000). Ter Braak et al., (2000) found that 40.5% of 
patients with type 1 diabetes attending an outpatient clinic had experienced at least 
one episode of severe hypoglycaemia. This is much higher than the 2% of 
patients with type 2 diabetes who had experienced severe hypoglycaemia in a 
study by van Staa, Abenhaim & Monerre (1997) reported in (Gerich, 2000). 
Patients with type 1 diabetes may also lose the ability to recognise the early signs 
of hypoglycaemia, placing them at a greater risk of severe hypoglycaemia. Gold, 
MacLeod, & Frier, (1994) found that patients with type 1 diabetes who had an 
impaired awareness of hypoglycaemia were six times more likely to experience 
severe hypoglycaemia than those patients with normal awareness. 
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Hypoglycaemia is an unpleasant and potentially dangerous side effect of diabetes 
treatment and can disrupt social and occupational functioning in some patients 
(Richmond, 1996). 
1.2. Fear of Hypoglycaemia - A review 
A possible link between the unpleasant experience of hypoglycaemia, fear and 
avoidance of hypoglycaemia, and maintaining elevated blood glucose was first 
suggested in the late 1970's and early 80's (Weiner & Skipper, 1979; Surwit, 
Scovern, & Feinglos, 1982). Fear of hypoglycaemia has been described not only 
in people with diabetes but also in parents of children with diabetes 
(Macrodimitris & Endler, 2001) and in spouses of patients with diabetes ( Gonder 
Frederick, Julian, Cox, Clarke, & Kovatchev, 1997). 
The literature relevant to fear of hypoglycaemia falls into three categories; studies 
investigating factors that affect glycaemic control, psychosocial factors affecting 
diabetes management in general, and finally a small body of work that specifically 
addresses fear of hypoglycaemia. Most of the studies that focus on fear of 
hypoglycaemia have used the Fear of Hypoglycaemia Scale (HFS) developed by 
Cox and colleagues (Cox, Gonder-Frederick, Nowacek, & Butterfield, 1987). The 
HFS measures both behavioural and cognitive (worry) aspects of fear of 
hypoglycaemia. 
1. 2.1. Diabetes-related factors 
The majority of published studies have focused on either patients with type 1 
diabetes only or those with type 2 that take insulin. Few studies have directly 
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compared type 1 with type 2 diabetes, however, Polansky, Davis, Jacobson, & 
Anderson, (1992) found fear of hypoglycaemia to be greater in those with type 1 
diabetes. 
The effect of previous experience of hypoglycaemia, particularly severe episodes, 
has been found to increase fear of hypoglycaemia. Irvine, Cox, & Gonder -
Frederick, (1992) found that the Behaviour Subscale of the HFS was related to the 
frequency of previous hypoglycaemia in patients with IDDM. The total HFS 
score ( combining behavioural and cognitive aspects) has been found to have a 
positive relationship with previous hypoglycaemia ( Costea, Ionescu-Tirgoviste, 
Cheta, & Mincu, 1993; Irvine et al., 1992; Ter Braak et al., 2000) and with the 
frequency of hypoglycaemia-related hospitalisations (Shiu & Wong, 2000) in 
patients with IDDM. (Polansky et al., 1992) also found that previous experience 
increased fear of hypoglycaemia in participants with type 1 but not in type 2 
diabetes. A survey of both type 1 and type 2 diabetes (Thompson, Cummings, 
Chalmers, Gould, & Newton, 1996) found that those who had experienced severe 
hypoglycaemia episodes were less likely to want to improve metabolic control, 
possibly due to fear of hypoglycaemia. 
The influence of previous severe hypoglycaemia has also been found to affect the 
level of fear of hypoglycaemia in parents of children with type 1 diabetes 
(Macrodimitris & Endler, 2001). This study of fear of hypoglycaemia in parents 
of children with type 1 diabetes in the United States found that fear of 
hypoglycaemia was positively correlated with the number of hypoglycaemic 
seizures during the past year. 
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Patients with reduced awareness of hypoglycaemia have also been found to score 
more highly on the HFS Worry Subscale but not the Behaviour Subscale 
(Hepburn et al 1994). Patients with reduced awareness are more likely to 
experience severe hypoglycaemia (Gold et al., 1994) therefore increasing the 
likelihood of fear of hypoglycaemia. 
Reduced ability to monitor blood glucose may also increase fear of 
hypoglycaemia. (Cox, Kiernan, Schroeder, & Cowley, 1998) compared sight-
impaired (reduced ability to read blood testing machines) to non-impaired patients 
with diabetes and found that those with visual complications were more worried 
about hypoglycaemia. 
Only one study has investigated the effect of the duration of diabetes. (Gafvels, 
Lithner, & Borjeson, 1993) found that although patients with a longer duration of 
diabetes were more concerned about chronic complications, they were less 
concerned about their diabetes management. 
Different types of diabetes medications have different risks of hypoglycaemia, but 
as many studies only include participants that are on insulin, the effect of different 
diabetes medications has not been directly addressed. 
1. 2. 2. Gender 
Females tend to score higher on both behaviour and worry sub scales and this is in 
line with other measures of anxiety where women generally score higher. 
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(Gafvels et al., 1993) questioned 448 patients in Northern Sweden who took 
insulin and found that men were less worried than women about hypoglycaemia 
and the risk of future complications. 
1.2.3. Ethnicity 
Studies have investigated fear of hypoglycaemia in European (e.g. Irvine, Cox, & 
Gonder Frederick, 1994; Costea et al., 1993), North American (e.g. Hepburn, 
Deary, MacLeod, & Frier, 1994; Irvine et al., 1994), and Asian populations (Shiu 
& Wong, 2000). However, there have been no published studies of fear of 
hypoglycaemia in New Zealand or Australia, and no study has directly attempted 
to investigate fear of hypoglycaemia across ethnic groups. 
1.2.4. Age 
Fear of hypoglycaemia has been found in children, and adolescents (Green, 
Wysocki, & Reineck, 1990) as well as adults. There is some evidence that there 
may be some differences depending on age but this has not been clearly 
established. (Eaton, Mengel, Mengel, & Larson, 1992) did not measure fear of 
hypoglycaemia but found better metabolic control improved with age in patients 
withIDDM. 
1. 2. 5. Anxiety and depression 
Anxiety and depression have been found to be associated with an increase in fear 
of hypoglycaemia (Costea et al., 1993; A. Irvine et al., 1992). Polansky et al., 
(1992) found higher HFS scores were associated with higher trait anxiety and fear 
on other measures in both type 1 and type 2. 
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1.2. 6. Personality 
Personality is likely to affect the measurement of fear of hypoglycaemia. 
Hepburn et al., (1994) in a large study of patients with IDDM found that 
personality accounted for more variance in HFS scores than any other factor. 
Hepburn et al. suggested that personality affects self-report and the assessment of 
symptoms by others. Neuroticism was found to be the biggest influence on the 
worry subscale of the HFS. Coping styles have also been found to affect 
metabolic control (Macrodimitris & Endler, 2001; Peyrot, McMurray, & Kruger, 
1999). White, Tata, & Burns, (1996) found that there was a relationship between 
poor metabolic control and, passive dependent coping style in 90 IDDM patients. 
1.2. 7. Psychosocial factors: 
Peyrot et al., (1999) compared personality, psychosocial resources and glycaemic 
control in patients with type 1 and type 2 diabetes. They found improved 
glycaemic control in people with stable psychosocial resources ( e.g. higher 
education, married, positive coping styles) whereas stress was associated with 
poorer metabolic control. 
1. 2. 8. Link between fear of hypoglycaemia and metabolic control 
Studies that directly ask participants if they fear hypoglycaemia have found that 
fear of hypoglycaemia decreases people's desire to improve metabolic control. 
Ramchandani et al., (2000) found that a fear of hypoglycaemia (self-reported) was 
a barrier to improving metabolic control in college students in the United States. 
(They also found that a fear of hyperglycaemia improved diabetes control.) 
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Thompson et al., ( 1996) concluded from a survey of people with diabetes that fear 
of hypoglycaemia was a significant impediment to achieving better glycaemic 
control in adults with type 2 diabetes. Liakopoulou, Korvessi, & Dacou-
Voutetakis, (1992) found that HbA1c (a measure of metabolic control) was 
significantly higher in adolescents who worried more about their diabetes. 
However, this has not been clearly shown in studies of fear of hypoglycaemia 
using HbA1c as a measure of metabolic control. Some authors have pointed out 
that HbA1c masks the daily fluctuations in blood glucose levels (Irvine et al., 
1994). This variability may be important in determining the risks of future 
hypoglycaemia. However, HbA1c remains the most commonly used and accurate 
measure of overall metabolic control (American Diabetes Association, 2000). 
1.2.9. Appropriate versus inappropriate fear 
It seems likely that excessive fear in some people is likely to compromise their 
metabolic control and in the longer term increase the risk of diabetes related 
complications; conversely, it also seems possible that a lack of fear could be 
harmful. Cox et al., (1987) suggest that for patients at greater risk of 
hypoglycaemia, particularly those with impaired awareness, a certain degree of 
fear may be a motivating factor to avoid the potentially life threatening condition 
of severe hypoglycaemia. Cox et al. further suggest that there is a normal range of 
fear of hypoglycaemia and that both elevated and suppressed levels may 
compromise good metabolic control. 
Irvine et al., ( 1994) introduced the concept of adaptive and maladaptive fear 
according to the risk of future hypoglycaemia. When the risk of hypoglycaemia is 
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high then a certain amount of fear is adaptive, whereas when the risk is low the 
same level of fear would be maladaptive. Similarly when the risk of 
hypoglycaemia is low ( e.g. when blood glucose is high) then no fear is adaptive, 
however, a high fear is maladaptive. Figure 1.1 (adapted from Irvine et al., 1994) 
summarises the relationship between the risk of hypoglycaemia and fear of 
hypoglycaemia. 
Risk of Hypoglycaemia 
High Denial Appropriate Fear 
Low 
0 Low High 
Fear of Hypoglycaemia 
... Adaptive 
c:::::::> Maladaptive 
Figure 1.1. Adaptive and maladaptive fear of hypoglycaemia as a function of the 
risk of hypoglycaemia (adapted from Irvine et al., 1994, p152). 
A simple linear model which conceptualises fear of hypoglycaemia solely as a 
result of previous exposure of a feared stimulus resulting in avoidance behaviour 
which in turn leads to poor metabolic control does not provide an adequate picture 
of the phenomenon. This has led some researchers to conclude that at present 
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most of the variance in fear of hypoglycaemia models remains unexplained 
(Hepburn et al., 1994; Irvine et al., 1994). 
1.3. Psychological aspects of diabetes 
There are disproportionately high rates of psychological disorders in patients with 
diabetes when compared to the general population (Rubin & Peyrot, 2001). 
Anxiety and depression are the two most common disorders in patients with 
diabetes (Gavard, Lustman, & Clouse, 1993). A study of patients with type 1 or 
type 2 diabetes, 28% reported moderate to severe levels of depression, anxiety, or 
both at the time of the interview (Lloyd, Dyer, & Barnett, 2000). However, 
another study found that although rates of anxiety and depression overall are 
higher in a diabetic population, they may not differ in the proportion who fall in 
the pathological range (Smari & Valtysdottir, 1997). Both depression and anxiety 
have been found to be greater in patients who are female, have more diabetes-
related complications, higher HbA1c, are unmarried, and are less educationed 
(Peyrot & Rubin, 1997). 
1. 3.1. Anxiety 
Rubin & Peyrot, (2001) suggests that patients with diabetes may experience 
higher levels of anxiety than the general population because they often have 
greater sources of fear such as hypoglycaemia, diabetes complications, regular 
blood testing, and insulin injections. 
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Anxiety has been found to negatively affect metabolic control in adults 
(Niemcryk, Speers, Travis, & Gary, 1990) and adolescents (Rempala, 1999). 
However, Rempala, found that anxiety was related to better metabolic control in 
pre-adolescents. Wiebe, Alderfer, Palmer, Lindsay, & et al., (1994) in a small 
study of adolescents with type 1 diabetes found that anxiety was related to poorer 
metabolic control, and anxious adolescents tended to attribute physiological 
sensations to hypoglycaemia more often than their less anxious peers. 
Liakopoulou et al., (1992) found that anxiety did not affect metabolic control in 
40 Greek adolescents. This study had only a small sample, however, HbA1c was 
significantly higher in those that worried more about their diabetes. 
Symptoms of anxiety, which include panic symptoms, are sometimes similar to 
that of hypoglycaemia. Steel, Masterton, Patrick, & McGuire, (1989) reported 
two case studies in which patients mistook hyperventilation for hypoglycaemia, 
leading to unnecessary treatment and high blood glucose levels. Conversely, 
panic attacks are not brought on by hypoglycaemia (Schweizer, Winokur, & 
Rickels, 1986). 
1. 3. 2. Depression 
Estimates of lifetime prevalence rates of major depression in patients with type 1 
and type 2 diabetes range between 14.4% and 32.5% (de Groot, Jacobson, 
Samson, & Welch, 1999). A meta analysis of 27 studies found a significant 
association between depression and diabetes complications ( de Groot, Anderson, 
Freedland, Clouse, & Lustman, 2001). 
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Depression, even at sub clinical levels may worsen metabolic control, possibly by 
decreased self-care (Van Tilburg et al., 2001) or at a physiological level by 
hormone dysregulation (Lustman, Griffith, & Clouse, 1998). Diabetes and 
depression share some symptomatology such as fatigue, changes in sleep, and 
appetite (Rubin & Peyrot, 2001 ). Treatment of depression has been shown to 
improve metabolic control (Lustman et al, 1998). The relationship between 
depression and diabetes, poor metabolic control and increased complications 
remains unclear, and the relationship may be different for different individuals, 
and type of diabetes ( de Groot et al., 2001). One study (Eaton, Pratt, Armenian, 
Ford, & Gallo, 1996) suggests that depression is an increased risk factor for the 
onset of type 2 diabetes. 
1.4. This Study 
This study makes and tests predictions of relationships between different variables 
and fear of hypoglycaemia. The factors investigated in this study and the 
predicted effects on fear of hypoglycaemia are shown in Figure 1.2. 
Factors in the top left box are predicted to have a positive relationship with fear of 
hypoglycaemia. There have been many studies that have found that patients with 
a fear of hypoglycaemia are more likely to have previously experienced 
hypoglycaemia. This is consistent with fear of hypoglycaemia as phobic 
avoidance of a feared situation. The more severe the past experience the more 
likely fear of hypoglycaemia is to develop. Patients with type 1 diabetes are also 
predicted to be more likely to develop fear of hypoglycaemia as they are more 
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susceptible to hypoglycaemia than patients with type 2 diabetes, even when using 
insulin. Type of medication has not been studied previously. It is predicted that 
there will be a hierarchy of fear of hypoglycaemia due to medication with the 
highest fear of hypoglycaemia in those on insulin, followed by sulphonylureas, 
metformin, and finally those that are not on diabetes medication ( diet controlled). 
This hierarchy is based on the action of the various medications and the 
corresponding probability of hypoglycaemia. 
Anxiety and depression have been found to be associated with higher fear of 
hypoglycaemia in previous studies and this is predicted in this study also. 
However, it should be noted that anxiety and depression might also directly affect 
metabolic control due to factors other than fear of hypoglycaemia such as 
compliance and motivation. Females are expected have greater fear of 
hypoglycaemia as this trend is common to most anxiety traits. 
Living alone has not been studied previously but it is predicted that this may 
increase fear of hypoglycaemia as there is a greater risk of developing severe 
hypoglycaemia if there is no one to assist with or identify early signs of 
hypoglycaemia. 
The middle box identifies factors that are predicted to be positively, but less 
strongly related to fear of hypoglycaemia. Patients with type 2 diabetes are 
expected to experience less fear of hypoglycaemia than type 1 diabetes. Some 
patients taking metformin, an oral diabetic medication that does not have 
hypoglycaemic action, and those that are diet controlled are still predicted to 
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experience some level of fear of hypoglycaemia due to misconceptions about 
diabetes. 
The box on the right side of Figure 1.2 contains factors that either have not been 
investigated previously or for which there are unclear or conflicting results. 
Ethnicity has not been included in other studies; however, this may be useful to 
consider in the New Zealand context, particularly as more Maori and Pacific 
Island People develop diabetes. Whether age and duration of diagnosis affect fear 
of hypoglycaemia has not been established yet. 
Once a fear of hypoglycaemia has been established it is likely that it will induce 
behavioural changes ( e.g. avoiding hypoglycaemia by keeping blood glucose high, 
testing more frequently then required) and cognitive changes ( e.g. increased worry 
about hypoglycaemia). These behavioural changes and cognitive processes are 
both negatively reinforced by short-term reduction in fear, and also serve to 
maintain fear levels. In some patients, but not necessarily all, the avoidance 
behaviour may involve compromising metabolic control by keeping blood glucose 
levels high. This in turn places the patient at a higher risk of developing diabetes 
related complications. 
As stated by (Irvine et al., 1994) a simple linear model is insufficient to explain all 
the variance in fear of hypoglycaemia and the model presented here is not 
expected to cover the complete range of possibilities. 
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✓ More severe 
hypoglycaemia 
✓ Type 1 diabetes 
✓ Medication - insulin 
and sulphonylureas 
✓ Anxiety* 
✓ Depression * 
✓ Female 
✓ Living alone 
Factors with a smaller 
positive effect 
✓ Type 2 diabetes 
✓ Metformin 
✓ Diet controlled 
Fear of Hypoglycaemia 




✓ Duration of diagnosis 
Cognitive and Behavioural changes 
are negatively reinforced by fear 
reduction 
-l., Metabolic Control 
(Increased blood glucose) 
Increased risk of Complications 
* These factors are predicted to affect fear directly but may also have a direct effect on metabolic 
control due to factors such as compliance and motivation issues. 
Figure 1. 2. Predicted factors that affect fear of hypoglycaemia and metabolic 
control. 
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In summary the aims of this study are 
• To identify the prevalence of fear of hypoglycaemia in the population 
attending the Christchurch Diabetes Centre. 
• To investigate the relationships between fear of hypoglycaemia and the 
following variables: type of diabetes, previous hypoglycaemia experience, 
metabolic control, diabetes medication, and demographic variables. 
• To determine the level of depression and anxiety and investigate the 




Participants in this study were all diagnosed with diabetes mellitus either type 1 or 
type 2 and were patients attending the Christchurch Diabetes Centre. This Centre 
is a tertiary referral clinic for greater Christchurch and draws patients from newly 
diagnosed cases in the community, long-standing cases with complications, and 
hospital admissions. Therefore, the patients attending tend to have type 1 diabetes, 
or more advanced and complicated type 2 diabetes that is unable to be managed 
solely by a general practitioner. The age range of patients seen at the Diabetes 
Centre is from approximately age 12 to 13 years upwards. 
Following approval from the Canterbury Ethics Committee, all patients booked to 
attend a clinic appointment with a physician at the Christchurch Diabetes Centre 
between 23 November 2000 and 26 January 2001 were screened for eligibility to 
participate in the study. All patients were eligible unless they met the following 
exclusion criteria: 
1. A request by the patient not to be involved in research projects (recorded 
in their diabetes clinic file). 
2. Reduced cognitive capacity such that that person could not complete the 
questionnaires. This was judged by the researcher by reading clinic files 
( examples of exclusion included a history of strokes resulting in significant 
cognitive deficits, and intellectual disability). 
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The researcher reviewing patient files carried out initial screening. Names of 
patients who were eligible to participate were then forwarded to the appropriate 
physician for confirmation of eligibility. 
2.2 Procedure 
All clinic attendees who met the criteria were sent a letter and an information 
sheet (see Appendix A) at least one week before their appointment informing 
them about the study and inviting them to participate during their clinic 
appointment. Patients were then approached in person when they attended the 
clinic for their appointment. Those who agreed to participate were asked to 
complete a consent form (see Appendix A). Participants were also asked to 
indicate whether they would like to be sent their individual results, whether they 
would like their general practitioner to be sent their results, and whether they 
would like to receive a summary of the results when the study was completed. 
Participants then completed questions about themselves and their diabetes history 
and two questionnaires described below. The participants were required to answer 
all questions themselves but assistance from others such as the researcher or 
relatives was acceptable where required. A Maori Health \-Vorker and Samoan 
Registered Nurse were available if further assistance was required. Enlarged 
forms were available for participants who were sight impaired. 
2.3 Measures 
Copies of the demographic and diabetes.history questions and the two 
questionnaires used in the study are in Appendix B. 
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2.3.1 Demographic and diabetes history questions 
These questions were designed to gather information regarding the participant's 
ethnicity and living situation. Information regarding the participant's diabetes 
history and management was also requested along with whether they were 
currently taking medications for anxiety and depression. 
The information from these questions and patient records, was used to group 
participants into the following categories according to diabetes treatment: 
• D - all participants not on medication - diet controlled 
• M - Participants on tablets with no hypoglycaemic action (metformin 
only). 
• S - Participants on tablets with hypoglycaemic action (sulphonylureas 
alone or sulphonylureas & metformin). 
• I - Participants on insulin (insulin alone, insulin & metformin, insulin & 
sulphonylureas, or insulin, metformin & sulphonylureas). 
Participants in categories D and M would not experience hypoglycaemia and were 
additionally coded as "cannot hypo1" whereas those in categories Sand I could 
have hypoglycaemic episodes and were therefore coded as "can hypo". 
1. "hypo" is a commonly used term to describe a hypoglycaemic episode. 
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2.3.2 Hypoglycaemia Fear Sun1ey (HFS) 
The Hypoglycaemia Fear Survey (HFS) is a 23 item, Likert scale, paper and 
pencil measure that is easily completed in five to ten minutes. It was developed as 
a clinical and research tool to measure the degree to which people with diabetes 
fear hypoglycaemia (Cox et al., 1987). The HFS has been validated in several 
overseas studies for use with adults (Irvine et al., 1994) and children (Green et al., 
1990) and has been found to be able to identify individuals at risk of poor 
metabolic control due to their beliefs and behaviours. 
The HFS consists of two subscales, Behaviour and Worry. The Behaviour 
subscale (10 items) captures what people do to avoid low blood sugar levels and 
how often they do it. Some of these behaviours are important for management of 
hypoglycaemic episodes (such as carrying fast-acting sugar at all times) but many 
others are not necessary for management of hypoglycaemia and serve as 
avoidance tactics that often result in higher blood glucose levels. As such, a low 
score on this subscale may indicate a healthy and safe management technique, and 
higher scores indicate that the individual may be managing less well. Conversely, 
a low behaviour score may indicate an increased risk for a hypoglycaemic episode 
as they are neglecting to monitor or plan for hypoglycaemia. 
The Worry subscale ( 13 items) measures cognitive factors that may influence how 
people manage their blood sugar levels. Very low levels may place an individual 
at risk of hypoglycaemia, as they may be unmotivated to manage their diabetes 
well. Moderate levels are probably useful for maintaining motivation for keeping 
blood glucose at the appropriate level. High scores above 40 may indicate that the 
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individual is fearful of hypoglycaemia and may avoid it by keeping blood glucose 
higher than necessary. 
The version of the HFS used in this study was modified with the consent of the 
developer of the scale, Daniel Cox. The North American term for hypoglycaemia 
(reaction) was substituted with the common term used in New Zealand (hypo). 
2.3.3 The Hospital Anxiety and Depression Scale (HADS) 
The Hospital Anxiety and Depression Scale (RADS) is a widely used measure of 
anxiety and depression for use in medical settings and has been designed to avoid 
items that may be endorsed due to physical rather than psychological symptoms 
(Zigmond & Snaith, 1983). The RADS has been shown to be an appropriate 
questionnaire for use with patients with diabetes in clinic settings (Lloyd et al., 
2000). It is a 14 item, Likert scale questionnaire that is rapidly completed and is 
acceptable to adolescent (White, Leach, Sims, Atkinson, & Cottrell, 1999) and 
adult medical populations. It has well validated psychometric properties 
(Herrmann, 1997; Johnston, Pollard, & Hennessey, 2000). The RADS can be 
divided into two subscales to give measures of anxiety (7 items), and depression 
(7 items). Each of these subscales can be divided into three levels of severity (0-7 
normal, 8-10 possible anxiety/depression, and 11-21 probable anxiety/depression). 
2.3.4 Glycosylated Haemoglobin (HbA1c) 
HbA1c is a recommended index of glycaemic control and gives an indication of 
control over the previous six to eight weeks (American Diabetes Association, 
2000). All patients attending clinic appointments routinely have HbA1c levels 
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measured by blood test prior to the clinic appointment or by capillary test at the 
clinic. HbA1c was also categorised as good, fair and poor to reflect the level of 
control and the corresponding risks of damage due to hyperglycaemia (Table 2.1 ). 
Although the demarcations of this categorisation are relatively arbitrary, they are 
used in clinical settings. 
Table 2.1. Metabolic control categories for HbA1c levels. 
HbA1c (mmL-1) Category 
<7 Good 
7.0 - 9.0 Fair 
>9.0 Poor 
2.4 Statistical Analysis 
Data was entered into a database in Microsoft Excel and then transferred to SPSS 
for analysis. Analysis included descriptive statistics, correlational analysis, Chi-
square analysis, analysis of variance (ANOVA), and regression analysis. All 
reported significance values are 2 tailed. 
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3. RESULTS 
3.1. Response rate 
Over the sampling period 316 patients attending the Diabetes Centre were 
approached to participate in the study. Of these, 281 (89%) completed the consent 
form, and 272 (86%) completed all questionnaires. The response rate of 86% is 
very favourable compared to previous studies at the Diabetes Centre where 
approximately 50% responded. 
3.2. Descriptive statistics 
3. 2.1. Ethnicity 
A breakdown of ethnic identity is shown in Table 3 .1. The majority of 
participants identified as Pakeha/New Zealand European with only 4% identifying 
as Maori and 2% as Pacific Island people. Twenty participants (7%) declined to 
answer this question. 
Table 3.1. Ethnicity of participants 
Ethnic identity Frequency Percent 
PakehatNew Zealand European 229 91 
Maori 8 3 
Maori and Pakeha 3 1 
Asian 5 2 
Pacific Island 5 2 
Other 4 1 
Total 252 100 
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There were proportionately more Maori with type 2 than type 1 diabetes (Maori 
made up 5% of type 2 but only 1.5% of type 1). Similarly, Pacific Island people 
made up 4 % of those with type 2 but none (0%) had a type I diagnosis. Sample 
sizes were too small to test whether these differences were significant. 
3. 2. 2. Gender, age and diagnosis 
There was a fairly even sex ratio, however slightly more males (52%) than 
females (48%) completed the questionnaires. There were no differences in the sex 
of type 1 and type 2 participants (males made up 53% and 52% of type 1 and type 
2 participants respectively and, females made up 47% and 48%). 
The average age of participants was 48 years (SD=19, range 12 to 86 years). 
Forty three percent of participants had a diagnosis of Type 1 diabetes while the 
remaining 57% had Type 2. As age of onset of type 1 diabetes is generally 
younger than for type 2 diabetes, this difference is reflected in the ages of the 
respondents in the study. The average age for participants with type 1 diabetes 
was 34 years (SD =17, n=116) and for type 2 was 59 years (SD=13, n=155). 
Figure 3 .1 shows the distribution of ages for each diagnosis and confirms that age 
and diagnosis are correlated and not independent variabies. Participants with type 
1 diabetes were likely to have been diagnosed for a longer time (M = 14 years, 
SD= 13, range 0.2 - 52 years) than those with type 2 (M = 9 years, SD= 8, 
range 0.1 - 54 years). An ANOVA found this to be a significant difference 
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Figure 3.1. Age distribution of participants with type 1 diabetes compared to 
participants with type 2 diabetes. 
3.2.3. Diabetes medication 
The combinations of different diabetes medications taken by participants can be 
seen in Table 3.2. Many of the participants were prescribed more than one type of 
diabetes medication, with some participants taking up to three different types. 
The majority (78%) of participants were taking insulin and 16% took a 
sulphonylurea (has hypoglycaemic action). Over all, 89% of participants were 
taking medication that can cause hypoglycaemia. The remaining 11 % were either 
taking metformin or were controlled by diet and lifestyle factors alone and should 
not be physiologically able to experience hypoglycaemia. 
As expected there were large differences in treatment regimes for type 1 and type 
2 participants. All participants with type 1 were on insulin compared to 61 % of 
those with type 2. 
Table 3.2. The percentage of participants with type 1, type 2 diabetes, and both 
types combined that take different diabetes medications. 
Diabetes Type 1(%) Type 2 (%) Type 1 & 2 
Medication (%) 
Insulin only 97 40 64 
Insulin and 0 1 1 
sulphonylureas 
Insulin, 1 5 10 
sulphonylureas and 
metformin 
Insulin and 2 15 3 
metformin 
Sulphonylureas only 0 7.5 4 
Sulphonylureas and 0 13 7 
metformin 
Metformin only 0 13.5 8 
Diet only 0 5 3 
Totals 100 100 100 
More than half of the participants had had a change in their medication in the 
previous twelve months (Figure.3.2). The range in time since medication was last 
changed was from 1 month up to 10 years (120 months) with the average being 11 
months (SD=15, N = 253). There was no difference between type 1 (M = 11 
months) and type 2 participants (M = 10 months). 
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Figure 3. 2. Time elapsed since the last time medication was changed 
for all participants. 
3. 2. 4. Previous experience of hypoglycaemia 
Table 3. 3. shows that two thirds ( 67%) of all participants had taken measures to 
avoid hypoglycaemia. Most (81 % ) had previously experienced hypoglycaemic 
symptoms and 3 8% reported that they had required help from others to manage a 
hypoglycaemic episode. 
Table 3. 3. Previous experience of hypoglycaemia of participant according to type 
of diabetes. 
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Type 1 Type2 Type 1 & 2 
(%) (%) (%) 
Prevent hypoglycaemia 94 47 67 
Experienced 96 71 81 
hypoglycaemia 
Help for hypoglycaemia 65 17 38 
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Significantly more participants with type 1 diabetes had acted to prevent 
hypoglycaemia than those with type 2 (Pearson Chi-square, x2[1] = 66.86, 
p<.001). Participants with type 1 diabetes were also more likely to have 
previously experienced hypoglycaemia (x2[1] = 27.68, p<.001), and to have 
required assistance to treat hypoglycaemia (x2[1] = 63.07, p<.001). 
3.2.5. Metabolic control 
Glycated haemoglobin (HbA1c) was used to assess metabolic control over the 
previous two months. The mean HbA10 of all participants was 8.3 (SD= 1.6, 
range 5.1 - 15.3). The mean for type 1 was 8.7 (SD= 1.8, range 5.5 - 15.3), which 
was higher than the mean for type 2 of 8. 0 (SD = 1. 5, range 5. 1 - 12.1 ). Although 
this difference was statistically significant (F[l,269], = 9.43, p = <.01), it is 
unlikely to be a clinically significant difference. 
Table 3 .4 shows that metabolic control in the sampled population was fairly 
evenly divided between good, fair and poor categories. 
Table 3. 4. The percentage of participants with good, fair and poor metabolic 
control for type 1, type 2 and both types combined. 
---
Metabolic HbA1cRange Type 1 Type2 Type 1 & 2 
Control 
Good <7 25 39 32 
Moderate 7.0-9,0 35.5 36 39 
Poor <9.0 42.5 25 29 
3. 2. 6. Medication for anxiety and/or depression 
The percentage of participants taking medication for depression and/or anxiety 
was 11 %. Slightly more participants with type 2 diabetes (15%) were on 
medication for depression or anxiety than those with type 1 (4%). A Pearson Chi-
square analysis found this to be a significant difference (x,2[1] = 8.57, p<.01). 
3.2. 7 Living alone, blood testing machine 
Overall 19% of participants lived alone. There was no significant difference 
between the percentage of participants with type 1 (14%) and type 2 (22%) who 
lived alone. 
Almost all those sampled (97%) had a blood-glucose testing machine at home. 
3.3. The Hospital Anxiety and Depression Scale 
The mean score of the HADS Anxiety Subscale for all participants was 6.4 
(SD=3. 9) and ranged from 0 to 18 out of a possible 21. The mean score for the 
Depression Subscale was 3.7 (SD= 3.2) with a range from Oto 15 out of a 
possible total of 21. 
Figure 3.3 shows that the majority of participants scored in the normal range of 
between 0 and 7 for both the Anxiety and Depression Subscales. In the Anxiety 
Subscale 27% of participants scored in the moderate range indicating possible 
anxiety and 16% fell in the higher range indicating probable anxiety. Fewer 
participants scored in the possible and probable ranges for the Depression 
Subscale (16% and 3% respectively). 
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There was a similar distribution of RADS scores when participants with type 1 
and type 2 are considered separately (Figure 3.4). There was no difference 
between the mean scores for anxiety ( type 1 M = 6 .13, SD = 3. 65; type 2 M = 
6.56, SD= 4.15; F[l,265] = .773, NS) or depression (type 1 M = 3.32, SD-= 3.10; 
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Figure 3.3. Distribution of scores for the Anxiety and Depression 
Subscales of the RADS for all participants. Scores 0-7 are normal, 8-
10 are possible anxiety/depression, 11-21 probable 
anxiety/depression. 
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Figure 3. 4. Distribution of scores for the Anxiety and Depression 
Subscales for the RADS for type 1 and type 2 diabetes separately. Scores 
of 0-7 are normal, 8-10 are possible anxiety/depression, 11-21 are 
probable anxiety/depression. 
The correlations between the anxiety and depression subscales can be seen in 
Table 3.5. Depression and anxiety were positively correlated (Pearson 
correlation, r = 0.616, p<0.001). 
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There was no relationship of either anxiety or depression with age, or years since 
diagnosis. There was a modest positive correlation between anxiety and HbA1c in 
participants with type 1 diabetes. 
Table 3.5. Results of Pearson correlation analysis for the RADS scores and 
HbA1c, age and years since diagnosis. 
BADS Anxiety BADS Depression 




Pearson 1.000 1.000 1.000 .605** .616** 
Correlation 
pvalue .000 .000 
N 114 153 272 114 153 
BADS 
Depression 
Pearson .605** .616** .616** 1.000 1.000 
Correlation 
pvalue .000 .000 .000 
N 114 153 269 114 156 
BbA1c 
Pearson .244** .010 .095 .158 -.001 
Correlation 
p value .009 .906 .122 .095 .986 
N 113 153 268 113 153 
Age 
Pearson -.039 -.119 -.025 .154 -.108 
Correlati 
on .679 .144 .679 .101 .183 




diagnosis -.060 .019 -.018 .038 .025 
Pearson 
Correlati .527 .816 .771 .686 .756 
on 114 153 269 114 153 
pvalue 
N 

















As shown in Table 3.6 the mean for females was significantly higher than the 
mean score for males in the anxiety subscale but there was no significant 
difference for depression. No differences were found for either subscale between 
type 1 and type 2 diabetes, or type of medication. Those who were taking 
medication for anxiety and or depression had significantly higher mean scores on 
both subscales. 
Mean anxiety was higher in those that had experienced hypoglycaemia in the past 
but not depression. Those who had required help for hypoglycaemia did not show 
any significant differences for anxiety or depression. 
There were no significant mean differences for anxiety or depression in 
participants who were living alone compared to those who were not. 
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Table 3. 6. The relationship between the RADS scores and sex, depression 
medication, and previous experience of hypoglycaemia. 
BADS Anxiety BADS DeJ)ression 
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Type 1 Type 2 Type 1 & Type 1 Ty11e 2 Type 1&2 
2 
Sex 
Female mean 6,96 7.64 7.38 3.20 4.45 3.95 
SD 3.92 4.08 4.02 3.14 3.27 3.28 
N 55 74 130 55 74 130 
Male mean 5.25 5.54 5.42 3.37 3.65 3.51 
SD 3.17 3.97 3.63 3.04 3.25 3.15 
N 59 79 139 59 153 139 
F 6.60 10.317 17.69 .089 2.30 1.28 
p value .012 .002 .000 .766 .131 .259 
Depression 
medication 
"Yes" mean 9.80 9.22 9.32 7.20 7.09 7.11 
SD 4.44 3.78 3.82 3.90 3.23 3.28 
N 5 23 28 5 23 28 
"No" mean 5.91 6.08 6.03 3.11 3.49 3.33 
SD 3.53 4.04 3.81 2.93 2.98 2.97 
N 109 130 241 109 130 241 
F 5,703 11.97 18.71 9.07 27.66 39.57 
pvalue .019 .001 .000 .003 .000 .000 
Prevent 
hypoglycaemia 
"Yes" mean 6.08 6.85 6.42 3.26 4.14 3,63 
SD 3.58 4.38 3,93 3.09 3.47 3.38 
N 107 72 181 107 72 181 
"No" 1nean 6.00 6.30 6.27 3.71 3.94 3.92 
SD 4.69 3.93 3.97 2.98 3.11 3.09 
N 7 81 88 7 81 88 
F .003 .672 .082 .141 .142 .483 
p value .953 .414 .774 .708 .707 .488 
Previous 
hypoglycaemia 
"Yes" mean 6.25 6.98 6.63 3.33 4.26 3.80 
SD 3,61 4.35 4.00 3.11 3.34 3.26 
N 109 108 219 109 108 219 
"No" 1nean 2.4 5.53 5.22 2.40 3.49 3.38 
SD 2.19 3.45 3.46 2.07 3.09 3.01 
N 5 45 50 5 45 50 
F 5.57 3,95 5.34 .436 1.77 .706 
pvalue .020 .049 .022 .511 .186 .401 
Table continued on next page. 
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Table 3. 6 (continued) 
BADS Anxiety BADS Deoression 




"Yes" mean 6.51 7.96 6.95 3.68 4.70 4.00 
SD 3.69 4.74 4.04 3.20 3.72 3.38 
N 74 27 102 74 27 102 
"No" mean 5.28 6.30 6.05 2.57 3.92 3.58 
SD 3.43 3,95 3.86 2.72 3.16 3.10 
N 40 125 163 40 125 163 
F 3.07 2.76 3.31 3.40 1.40 1.09 
p value .083 .066 .070 .068 .248 .298 
3.4. The Fear of Hypoglycaemia Scale 
The Behaviour Subscale mean score for all participants was 13.4 (SD= 8.3, 
N = 272) and ranged from Oto 38 out of a possible total of 40. The distribution of 
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Figure 3. 5. Distribution of scores for the Behaviour Sub scale of the HFS 
for all participants. 
The Worry Subscale mean score for all participants was 13.9 (SD= 12.9, 
N = 272) and ranged from Oto 52 out of a possible 52. The distribution of scores 
is shown in Figure 3.6 and, like the behaviour subscale, is negatively skewed. 
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Figure 3. 6. Distribution of scores for the Worry Sub scale scores of the 
HFS for all participants. 
The Total HFS Score is the sum of the Behaviour and Worry Subscales. The 
mean total HFS score was 27.3 (SD= 18.8, N=272) and ranged from Oto 90 out 
of a possible total of 92. The distribution of scores is shown in Figure 3. 7. 
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It was found that 16% of participants had a fear of hypoglycaemia as defined by a 
cut off score of 45 on the Total HFS score (approximately 1 standard deviation 
above the mean). Seventeen percent had little or no fear of hypoglycaemia as 
defined by a cut off of 10 on the Total HFS score (approximately 1 standard 
deviation below the mean). A Pearson Correlation analysis found a significant 
relationship between the behaviour and worry subscales (r = 0.55, p<0.0001) 
which indicates a link between worry associated with hypoglycaemia and 
behavioural management of diabetes. 
The results of a 2-tailed Pearson Correlation between the scores from the HFS and 
the other continuous variables investigated are reported in Table 3.7. 
Age was found to be significantly negatively correlated with all three scores from 
the HFS when diagnosis was combined. The Behaviour Subscale showed the 
largest correlation and suggests that older participants were less likely to avoid 
hypoglycaemia by changing their behaviour. However, there was no relationship 
between age and fear of hypoglycaemia when each diagnosis was considered 
separately. 
Metabolic control (measured by HbA1c) had a small positive correlation with all 
three measures of the HFS, indicating that poor metabolic control has some 
association with higher scores on this measure. 
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Table 3. 7. Results of Pearson Correlation analysis for HFS and age, HbA10, 
anxiety, depression, duration of diagnosis and time since medications changed. 
Behaviour Subscale Worry Subscale Total HFS 
Ty}le 1 Type2 Type Type 1 Type2 Ty(le Type 1 Ty1le 2 Type 
1&2 1&2 1&2 
AGE 
Pearson .124 ,038 -.307* .119 -.156 -.187* .139 -.096 -.263* 
Correlation 
P value .186 .641 .000 .204 .052 .002 .137 .232 .000 
N 116 156 272 116 156 272 116 156 272 
HbA1c 
Pearson .087 .065 .162** .166 .025 .130* .161 .044 .160** 
Correlation 
P value .355 .424 .008 .077 .759 .033 .086 .583 ,008 
N 115 156 271 115 156 271 115 156 271 
RADS 
Anxiety 
Pearson .337** .254** .201 ** .583** .610** ,568** .576** .542** .480** 
Correlation 
P value .000 .002 .001 .000 .000 .000 .000 .000 .000 
N 114 153 269 114 153 269 114 153 269 
RADS 
De1n·ession 
Pearson .253** .102 .062 .511 ** .321 ** .353** .488** .272** .271** 
Correlation 
Pvalue .007 .211 .310 .000 .000 .000 .000 .001 .000 
N 114 153 269 114 153 269 114 153 269 
Years since 
diagnosis 
Pearson .137 ,394** .321 ** .179 .071 .169** .190* .213** .275** 
Correlation 
P value .144 .000 .000 .055 .382 .005 .041 ,008 ,000 




Pearson .107 .157 .123 .181 .094 .138 .181 .132 .149 
Correlation 
P value .265 .063 253 ,058 .266 253 .057 .118 253 
N 111 141 252 111 141 252 111 141 252 
Behaviour 
Subscale 
Pearson 1.000 1.000 1.000 .445** .541 ** .553** .725** .798** .819** 
Correlation 
P value .000 ,000 .000 .000 .000 .000 
N 116 156 272 116 156 272 116 156 272 
Worry 
Subscale 
Pearson .455** .541 ** ,553** 1.000 1.000 1.000 .939** .938** .931 ** 
Correlation 
P value .000 .000 .000 .000 .000 .000 
N 116 156 272 116 156 272 116 156 272 
** level of significance p<.001 
Anxiety (RADS Anxiety Subscale) was found to have a modest positive 
correlation with the Behaviour Subscale of the HFS and a stronger positive 
correlation with the Worry Subscale and the HFS total score. This indicates an 
association between the level of anxiety and the cognitions of patients about 
hypoglycaemia in particular. Depression (RADS Depression Subscale) was found 
not to be correlated with the Behaviour Subscale but was moderately correlated 
with the Worry Subscale. 
The time since diagnosis of diabetes had a small to moderate positive correlation 
with all three measures of the HFS indicating that fear of hypoglycaemia may 
increase with the duration of the illness. The time since medication was changed 
was not significantly correlated with any of the HFS scores. 
Analysis if Variance (ANOVA) was used to compare the HFS scores for the 
discrete variables such as gender, ethnicity, diagnosis, medications and diabetes 
questionnaire items. Table 3.8 shows that females scored significantly higher than 
males when diagnosis was analysed separately and together for all three HFS 
scales with one exception; no significant difference was found between female 
and male means for the behaviour subscaie in participants with type 1, although 
the trend was in the same direction. 
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Table 3.8. Comparison ofHFS Scores for males and female participants 
Behaviour Subscale Worry Subscale Total HFS Score 
Type Type Type Type Type Type Type Type Type 
1 2 1&2 1 2 1&2 1 2 1&2 
Female Mean 19.79 11.46 15.05 20.14 14.11 16.71 39.93 25.57 31.75 
SD 5.88 7.81 8.15 12.23 14.62 13.92 15.71 19.77 19.43 
N 56 74 130 56 74 130 56 74 130 
Male Mean 17.77 7.51 11.85 15.73 8.17 11.37 33.50 15.68 23.21 
SD 5.64 6.73 8.02 10.80 10.79 11.39 14.11 15.41 17.25 
N 60 82 142 60 82 142 60 82 142 
F 2.90 11.50 10.58 4.25 8.43 12.08 5.39 12.26 14.75 
11 value .092 .001 .001 .041 .004 .001 .022 .001 <.001 
Sample sizes were too small to enable statistical comparisons to be made between 
the scores of the HFS for different ethnic groups. However, the mean scores have 
been reported as they suggest that ethnicity may be an area for future research. 
New Zealanders of European decent had higher mean scores, particularly in the 
behaviour subscale, than Maori participants. Pacific Island participants also had a 
lower mean score than New Zealanders of European decent for the behaviour 
subscale and their mean worry score was almost half that of scores of New. 
Zealand Europeans and Maori. Asian participants scored higher than any other 
ethnic group, however, one very high individual score is likely to have skewed the 
results. 
44 
Table 3.9. Comparison ofHFS scores for different ethnic groups 
Behaviour Worry TotalHFS 
Subscale Subscale Score 
ETHNICITY 
NZ European Mean 
SD 13.67 14.09 27.76 
N=227 8.29 13.13 19.16 
Maori Mean 7.88 13.37 21.25 
SD 4.19 14.21 14.06 
N=8 
NZ European/Maori 7.33 7.33 14.67 
Mean 11.02 5.03 12.22 
SD 
N=3 
10.00 7.80 17.80 
Pacific Island Mean 6,2 6.57 11.32 
SD 
N=5 
18.20 25.00 43.20 
Asian Mean 6.30 17.18 19.50 
SD 
N=5 
9.25 5.75 15.00 
Other Mean 15.94 10.84 26.72 
SD 
N=4 
13.36 13.94 27.31 
Total Mean 8.37 13.14 19.14 
SD 
N=252 
Participants with type I diabetes scored significantly higher on all three HFS 
scales than those with type 2 diabetes (Table 3 .10). 
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Table 3.10. Comparison ofHFS scores between participants with type 1 and type 
2 diabetes. 
Behaviour Worry Total HFS 
Subscale Subscale Score 
DIAGNOSIS 
Type 1 Mean 18.74 17.86 36.60 
SD 5,82 11.67 15.18 
N=ll6 
Type2Mean 9.83 10.99 20,37 
SD 7.50 13.05 18.24 
N=l56 
F 124.564 20,180 60,622 
pvalue J)<. 001 p<,001 p<.001 
There was a significant relationship between scores on the Behaviour Subscale 
and the Total HFS Score, and type of diabetes medication (Table 3. 11 ). 
Table 3.11. Comparison between HFS scores for different diabetes medications. 
Behaviour Subscale Worry Subscale Total HFS Score 
Type2 Type 1&2 Type 2 Type 1&2 Type 2 Type 1&2 
MEDICATION 
I Mean 12.08 15.74 12.58 15.48 24.66 31.23 
SD 7.41 7.36 12.77 12.43 17.74 17.39 
N 95 211 95 211 95 211 
A Mean 6.25 6.25 9.41 9.41 15.66 15.66 
SD 5.44 5.44 13.35 13.35 16.65 16.65 
N 32 32 32 32 32 32 
BMean 3.76 3.76 7.62 7.62 11.38 11.38 
SD 4.72 4.72 13.13 13.13 16.92 16.92 
N 21 21 21 21 21 21 
DMean 4.63 4.63 7.25 7.25 11.88 11.88 
SD 7.09 7.09 14.31 14.31 20.43 20.43 
N 8 8 8 8 8 8 
F 13.65 36.60 1.32 4.91 5.12 16.39 
P value .000 .000 .270 .002 .002 .000 
When all diagnoses are combined there is a clear hierarchy of fear of 
hypoglycaemia with participants on insulin exhibiting a greater fear of 
hypoglycaemia than all other types of medication, and participants on 
sulphonylureas showing the next highest scores (Figure 3.8). There is little 
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Figure 3. 8. Relationship between types of diabetes medication and mean 
scores for the Behaviour andWorry Subscales and the Total HFS Score for 
all participants. 
Participants who can experience hypoglycaemia score significantly higher on ali 
three HFS scores compared to those who cannot (Table 3 .12). However, in the 
group that cannot physiologically experience hypoglycaemia three participants 
scores fell in the high fear of glycaemia range. 
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Table 3.12. Comparison ofHFS scores for participants that can and cannot 
experience hypoglycaemia. 
Behaviour Worry Total HFS 
Subscale Subscale Score 
CANHYPO 
Can hypo Mean 14.49 14.68 29.18 
SD 7.82 12.70 18.05 
N=116 243 243 243 
Can't hypo Mean 4.00 7.52 11.52 
SD 5.35 13.20 17.58 
N=l56 29 29 29 
F 49.40 8.19 24.93 
p value .ooo .005 .000 
When HbA1c is put into categories to indicate goodness of metabolic control, there 
is a significant difference in the behaviour scores of the HFS (Table 3.13). 
Participants with good metabolic control have a lower mean behaviour subscale 
score than those that have fair and poor control. This was also found for the total 
HFS score. The mean differences in the worry scores were not significantly 
different between the three groups; however, the trend of the mean scores was in 
the direction of increasing scores associated with poor control. Multiple 
comparison analysis showed that the significant different found in the behaviour 
and total HFS subscales was due to differences between the "Good" group when 
compared to the "Fair" and "Poor" groups (Table 3 .14). 
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Table 3.13. Results of the ANOVA between Metabolic Control and HFS Scores. 
Metabolic Control Behaviour Subscale Worry Subscale Total HFS Score 
Good 
Mean 11.13 11.91 23.03 
SD 8.11 13.53 19.10 
N=86 
Fair 
Mean 14.72 14.72 29.45 
SD 8.23 12.57 18.83 
N=105 
Poor 
Mean 13.97 14.99 28.96 
SD 8.07 12.68 17.93 
N=80 
F 4.928 1.521 3.26 
P value .008 .220 .040 
Table 3.14. Multiple comparisons for metabolic control categories for the 
behaviour and HFS total scores. 
Dependent Metabolic control Mean Significance 
variable difference (p) 
Behaviour Good Fair -3.60 ,003** 
subscale Poor -2.85 .025* 
Total HFS Good Fair -6.41 .019* 
Poor -5.93 .042* 
There was no relationship between any of the three HFS variables and depression 
medication. 
Participants who reported that they took measures to avoid hypoglycaemia had 
significantly higher mean scores on all HFS measures, except for those with type 
1 diabetes (Table 3 .15). However, the number of participants with type 1 diabetes 
who did not take measures to prevent hypoglycaemia was very small. 
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Table 3.15. Comparison between HFS scores for participants with different levels 
of metabolic control. 
Behaviour Subscale Worry Subscale Total HFS Score 
Type Type Type Type Type Type Ty1le TyJle Type 
1 2 1&2 1 2 1&2 1 2 1&2 
Prevent 
Hypoglycaemia 
'Yes' Mean 19.00 13.03 16.60 17.95 13.32 16.09 36.95 26,34 
SD 5.66 6.44 6.65 11.66 13.34 12.53 15.14 17.67 
N 109 73 182 109 73 182 109 73 
'No' Mean 14.71 6.18 6.84 16.43 8.94 9.52 31.14 15.12 
SD 7.25 6.91 7.27 12.66 12.52 12.63 16.05 17.17 
N 7 83 90 7 83 90 7 83 
F 3,64 40.61 121.83 .122 4.46 16.48 .963 16.14 
p value .059 .000 .000 .739 .036 .000 .328 .000 
Experienced 
Hypoglycaemia 
'Yes' Mean 18.84 11.80 15.33 18.36 12.89 15.64 37.20 24.69 
SD 5.65 7.10 7.31 11.60 13.62 12.91 15.02 18.21 
N 111 110 221 111 110 221 111 110 
'No' Mean 16.60 3.61 4.88 6,8 6.43 6.47 23.40 10.04 
SD 9.53 4.83 6.60 7.53 10.37 10.07 13.94 13.71 
N 5 46 51 5 46 51 5 46 
F .705 51.18 87.80 4.85 8.31 22.53 4.06 24,03 
p value .403 .000 ,000 .030 .005 .ooo .046 .000 
Help with 
HyJloglycaemia 
'Yes' Mean 19.71 16.41 18.83 20.36 20.41 20.37 40.07 36,81 
SD 5.74 7.26 6.31 12.58 16,69 13.70 16.01 21.43 
N 75 27 102 75 27 102 75 27 
'No' Mean 16.98 7.84 10.11 13.29 8.95 10.12 30,27 16.78 
SD 5,61 6.67 7.50 8.10 11.29 10,80 11.18 15.48 
N 41 128 166 41 128 166 41 128 
F 6.01 18.69 96.12 10.53 9.73 46.23 12.11 16.61 
p value ,015 .000 .000 .002 .000 .000 .001 ,000 
~ 
Participants who had experienced hypoglycaemia had significantly higher mean 
scores on all HFS scores except for the behaviour subscale for those with type 1 
and again the number of those who had not taken measures to avoid 

























manage hypoglycaemia scored more highly that those that had not on all HFS 
scores. 
Univariate analysis of variance shows that the model presented accounts for 55% 
of variance in the Total HFS score. The variables that have the strongest 
relationship are the HADS Anxiety Subscale (F[l,12] = 57.84, p < .0001), 
previous hypoglycaemia requiring help from others (F[l,12] = 21.41, p < .0001), 
and diagnosis (F[ 1.12] = 6.11, p < . 05). 
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4. DISCUSSION 
The results of this study add to the understanding of fear of hypoglycaemia and 
will be discussed in terms of the model presented earlier in figure 1.2. Before 
these results are interpreted it is useful to consider how representative the sample 
is with reference to diabetes clinic populations and that of people with diabetes in 
the community. The lack of independence between age and type of diabetes, and 
the nature of anxiety and depression in this population are also discussed. 
4.1. How representative is the sample? 
Maori and Pacific Island People were likely to be under represented compared to 
New Zealanders of European descent. There is no recent information of the 
ethnic identities of people attending the Christchurch Diabetes Centre, however, 
Lunt (1993) reported that Maori made up 6% of clinic attendees in 1991. Since 
this time diabetes has been increasing more rapidly in Maori than in people of 
European descent (Health Funding Authority, 2000) and so it was expected that 
Maori would account for more than 6% of patients attending the clinic. The 
present study included only 3 to 4% Maori participants. Pacific Island people 
made up only 2% of participants and are also likely to be under represented. 
Possible barriers leading to under representation of these ethnic minorities may 
include cultural differences in attitudes towards participating in research, and 
English as a second language for some Pacific Island people. Over-sampling of 
ethnic minorities is needed before results of studies into fear of hypoglycaemia 
can be generalised to these ethnic groups. 
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Ethnicity aside, the sample can be considered to be representative of people with 
diabetes who attend a tertiary diabetes clinic as the overall response rate was very 
good. Both genders are evenly represented and there is a wide age range included. 
Type 1 and type 2 diabetes are evenly represented, however, this reflects the clinic 
population rather than people with diabetes in the community. People with type 1 
diabetes made up 43% of the sample but accounts for only five to ten percent of 
all people with diabetes in New Zealand (Health Funding Authority, 2000). 
As a clinic population was used for the study, the participants are characteristic of 
people with diabetes that is more advanced or less well controlled. As such, this 
sample contained more people on insulin therapy (78%) than in the community 
(14%; Scott & Brown, 1991). The majority of participants had medication 
changes in the previous six months, which again reflects the more complex nature 
of patients attending the centre. 
4.2. Age and diagnosis are not independent 
Age and diagnosis are not independent variables. The mean age distribution of 
participants with type 1 diabetes is skewed towards the younger ages, whereas the 
distribution of age for type 2 diabetes is skewed towards the older ages. As type 1 
diabetes is generally diagnosed in childhood through to young adulthood, there is 
a significant number of patients in this age group, with numbers decreasing with 
age. Type 2 diabetes is generally not diagnosed until middle adulthood and 
prevalence increases with increasing age, therefore there are very few patients 
with type 2 diabetes under the age of 30 years in this study, and numbers peak 
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around the 50 to 55 years age group. Therefore it is difficult to separate the effect 
of age from diagnosis unless each diagnosis is analysed separately. 
4.3. Anxiety and depression in a diabetes clinic population 
The RADS was found to be a quick and acceptable tool for assessing anxiety and 
depression in participants in this study. However when interpreting RADS· 
results, it needs to be considered that the RADS is not a diagnostic test for anxiety 
or depression, rather it is an indication of whether further assessment of these 
conditions is required. 
The levels of anxiety and depression in participants of this study indicated by the 
RADS were higher than that expected to be found in the general population. 
Sixteen percent of participants scored in the range for probable anxiety and 27% 
scored in the possible anxiety range, together accounting for 43% of the sample. 
The Christchurch Psychiatric Epidemiology Study (Oakley-Browne, Joyce, Wells, 
Bushnell, & Hornblow, 1989; Wells, Bushnell, Hornblow, Joyce, & Oakley-
Browne, 1989) found that the six-month prevalence rate in the general population 
for anxiety disorders was 8.4%. 
Depression rates were lower than anxiety in the present study with 3 % of 
participants scoring in the probable range and 16% in the possible range, together 
accounting for 19% of the sample. The Christchurch Psychiatric Epidemiology 
Study (Oakley-Browne et al., 1989; Wells et al., 1989) found that the six-month 
prevalence rate in the general population for affective disorders was 9.4%. 
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The higher levels of anxiety and depression found in this study are in line with 
other studies that have also found levels of anxiety and depression are higher in 
medical populations than the general population (Herrmann, 1997). Another 
study of patients with diabetes found that 28% of patients with type 1 and type 2 
diabetes had moderate to severe levels of anxiety, depression, or both as measured 
by the HADS (Lloyd, Dyer, & Barnett, 2000). Eggleston, (2002) investigated 
anxiety and depression in patients with cancer attending out-patient clinics at 
Christchurch Hospital and levels of anxiety ( 16% possible anxiety, 12% probable 
anxiety) and depression (9% possible and 5% probable depression) - also at higher 
levelsthan that in the general population. 
In this study females scored more highly than males for anxiety but there was no 
difference for depression. This is consistent with results from the Christchurch 
Psychiatric Epidemiology Study (Oakley-Browne et al., 1989; Wells et al., 1989) 
that found females had more anxiety disorders when compared to men but there 
was no difference for depression. This pattern is also typically found in RADS 
results in other studies (for a review see Herrmann, 1997; diabetes Lloyd et al., 
2000). 
There was no significant difference in levels of anxiety or depression in 
paiticipants with type 1 diabetes than participants with type 2 diabetes. This result 
is consistent with Lloyd et al., (2000) where no difference in RADS scores was 
found for patients with type 1 and type 2 diabetes. There was no relationship with 
duration of diagnosis, which is also consistent with Lloyd et al., (2000). 
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Despite finding no difference in anxiety or depression between participants with 
type 1 and type z diabetes, significantly more participants with type Z were taking 
medication for anxiety or depression and these participants scored more highly on 
both subscales of the HADS. It is unclear why more participants with type 2 were 
on medications for anxiety or depression. This difference maybe due, at least in 
part, to the older average age of participants with type 2 diabetes. 
There was no relationship of anxiety or depression with age. Lloyd et al., (2000) 
also found no linear relationship between anxiety or depression and age in patients 
with diabetes. However, epidemiological studies (Oakley-Browne et al., 1989) 
have found affective disorders increase with age whereas anxiety disorders remain 
relatively constant throughout the age range of 18 to 64 years. 
There was a modest to strong correlation between previous hypoglycaemia and 
anxiety. Other cross sectional studies in different medical populations, including 
cancer and cardiac, have found anxiety correlated with the severity of symptoms 
(Herrmann, 1997). Depression was not correlated with previous hypoglycaemia. 
Higher HbA10 levels were correlated with higher anxiety scores only in 
participants with type 1 diabetes indicating a link between anxiety and metabolic 
control. Lloyd et al., (2000) also found that anxiety affected HbA1c but only in 
men with high anxiety and moderate to severe depression. Depression was not 
correlated with HbA1c in this study. As the analysis is correlational no causal 
conclusions can be drawn. It is possible that anxiety affects management of blood 
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glucose either at a behavioural or physiological level; however, high blood 
glucose levels could potentially cause people to feel more anxious. 
Contrary to predictions, participants that lived alone did not score more highly for 
anxiety or depression. Previous studies had found an association between RADS 
scores and psychosocial factors (Herrmann, 1997). Living alone may be a 
psychosocial stressor for some but not all participants. 
In summary, the results of the RADS in this study are consistent with other 
studies that indicate that levels of anxiety and depression are higher in medical 
populations than the general population. Females scored more highly for anxiety 
than men but there was no difference between sexes for depression. There was 
also no difference between participants with type 1 and type 2 diabetes despite 
more of those with type 2 taking medication for anxiety or depression, and a 
greater average age. Previous experiences of hypoglycaemia and higher HbA1 c 
have also been found to be associated with anxiety (but not depression) in some 
participant groups. Correlational analysis does not allow testing of causal 
relationships and so the nature of these relationships remains speculative. 
4.4. Prevalence off ear of hypoglycaemia 
Eighteen percent of participants had a high fear of hypoglycaemia. It is difficult 
to compare this result to other studies for the following reasons: 
• There are several different versions of the HFS that have been used by 
different studies. Differences with the Worry Subscale are the most prevalent 
differences with some studies using a 13 item version ( e.g. the present study; Cox, 
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Gonder-Frederick, Nowacek, & Butterfield, 1987; Irvine, Cox, & Gonder 
Frederick, 1990; Irvine, Cox, & Gonder Frederick, 1994; Polonsky, Davis, 
Jacobson, & Anderson, 1992; Ter Braak et al., 2000) whereas others have used a 
17 item Worry Subscale version (e.g. Hepburn, Deary, MacLeod, & Frier, 1994; 
Irvine, Cox, & Gonder Frederick, 1992; Shiu & Wong, 2000). 
• Different criteria are used to define a fear of hypoglycaemia. This study has 
used one standard deviation above the mean as an arbitrary cut-off point. (Shiu & 
Wong, 2000) also used one standard deviation above the mean and found that 
15% of their sample had a high fear of hypoglycaemia. Most other studies have 
not defined a cut-off for a high level of fear. 
• Different studies have adapted the HFS to suit their own population. For 
example, Green, Wysocki, & Reineck, (1990) made adaptations for a child 
population, and translations have been made into Romanian (Costea et al., 1993), 
and Mandarin (Shiu & Wong, 2000). The present study also adapted the scale to 
suit a New Zealand population by replacing North American terms with those 
used in New Zealand. 
Despite the above problems, mean scores of subscales can be compared for a 
number of studies. Early studies using the HFS reported scores for the behaviour 
and worry subscales that were greater than those found in this study (Cox et al., 
1987; Irvine et al., 1990; Irvine et al., 1994; Polonsky et al., 1992). However, Ter 
Braak et al., (2000) reported results for the Worry Subscale that were similar to 
this study. Most of the earlier studies only surveyed patients with type 1 diabetes 
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which may have lead to higher scores, however, when type 1 scores from this 
study are compared, the scores from the present study are still lower. This could 
be due to differences in recruitment methods or may reflect a cultural difference. 
Some studies have discarded the Behaviour Subscale and have used the Worry 
Sub scale as a stand-alone measure of fear of hypoglycaemia. The Behaviour 
Subscale is not a pure linear measure as it contains some items that are important 
for good metabolic control and should always be done ( e.g. item 8. "I carry fast 
acting sugar with me"), other items that should be done when appropriate or in 
moderation (e.g. item 9. "I avoid exercise when I think my blood sugar is low") 
and others that are inappropriate (e.g. item 3. "ifl test my blood sugars, I keep 
them a little high to be on the safe side"). In contrast the Worry Subscale is 
straight forward and is a simple measure of how often people worry about 
different aspects of diabetes ( e.g. item 11. "I worry about not recognising/ 
realising I am having a low blood sugar"). There is a correlation between the two 
subscales, indicating a link between worry and behaviour. However, both 
subscales provide different and useful information in the analysis of fear of 
hypoglycaemia. The present study shows that each subscale has different 
relationships with different factors. For example, behaviour is correlated with 
HbA1c in participants with type 1 diabetes whereas the Worry Subscale is not. 
As a research and clinical tool the HFS is acceptable to patients and is quickly 
completed. It provides useful information at a clinical level, particularly as a 
quick assessment of behaviour that may be compromising diabetes management. 
However, as a research tool there needs to be a version that is consistently used to 
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enable direct comparisons between studies. More research is needed into 
developing normative scores and cut-off scores for both high fear and low fear 
that are meaningful at a clinical level. 
4.5. Fear of hypoglycaemia model 
The model presented in figure 1. 2 describes the predicted influence of factors on 
fear of hypoglycaemia. The factors that were predicted to have the largest 
positive effect on fear of hypoglycaemia were previous experience of 
hypoglycaemia, severity of hypoglycaemia, type 1 diabetes, medications with 
hypoglycaemic action, anxiety, depression and living alone. The characteristics of 
each of these variables and their relationship with fear of hypoglycaemia are 
discussed below. 
4. 5.1. Previous hypoglycaemia 
Almost all participants with type 1 diabetes (94%) had taken measures to prevent 
hypoglycaemia. It was expected that all type 1 participants would have taken such 
measures as all were on insulin therapy. Fewer participants with type 2 diabetes 
( 4 7%) had taken measures to avoid hypoglycaemia. As 11 % of participants with 
type 2 diabetes were not taking medication with a hypoglycaemic action and 
therefore should not experience hypoglycaemia, not taking measures may be an 
appropriate response. However, for the remaining 6% of participants with type 1 
diabetes and 32% of participants with type 2 diabetes that may experience 
hypoglycaemia due to medication effects, by not taking measures to avoid 
hypoglycaemia they are at risk of hypoglycaemic episodes. 
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Almost all participants with type 1 diabetes (96%) and the majority of those with 
type 2 diabetes (71 % ) had previously experienced hypoglycaemia, indicating that 
most patients are at risk of hypoglycaemia if their diabetes is not well controlled. 
Significantly more participants with type 1 diabetes had required help to manage 
hypoglycaemia than participants with type 2 diabetes ( 65% and 17% 
respectively). This reflects the increased risk of hypoglycaemia for people with 
type 1 diabetes compared to type 2 diabetes. 
Overall the responses from participants confirm that people with type 1 diabetes 
experience hypoglycaemia more often and when they do it is likely to be more 
severe. This experience is likely to increase the likelihood of developing fear of 
hypoglycaemia in type 1 diabetes compared to type 2. 
The link between experience of hypoglycaemia and increased HFS scores was 
found in all participants with type 1 and type 2 diabetes in this study. Other 
studies have also found that previous experience of hypoglycaemia has an 
important association with fear of hypoglycaemia measures. Gold et al., (1997) 
found a history of severe hypoglycaemia accounted for over 25% of variance on 
the worry subscale in patients with IDDM. Ter Braak et al., (2000) also found 
those with more severe hypoglycaemia experience had significantly higher mean 
scores on the HFS worry. 
The results from this study support the prediction that previous experience and 
severity of hypoglycaemia is involved with the development of fear of 
hypoglycaemia. 
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4. 5.2. Diagnosis 
As expected, diagnosis had a large effect on fear of hypoglycaemia. Participants 
with type 1 diabetes on average scored higher than participants with type 2 
diabetes on all measures of the HFS. This has also been found by all other studies 
that have compared participants with type 1 and type 2 diabetes (Polonsky et al., 
1992; Shiu & Wong, 2000). As discussed above, patients with type 1 diabetes are 
more likely to experience hypoglycaemia, particularly more severe episodes, than 
patients with type 2 diabetes. Therefore this group are more likely to develop a 
phobic response to hypoglycaemia. 
The duration of diagnosis was a factor that had an unpredicted effect on fear of 
hypoglycaemia. The results show that duration of diagnosis has a modest 
correlation with the Behaviour Subscale for participants with type 2 diabetes. As 
participants with type 2 diabetes progress to sulphonylureas and/or insulin therapy 
the risk of hypoglycaemia increases and it becomes necessary to change behaviour 
to avoid hypoglycaemia. In contrast, participants with type 1 are on insulin from 
the time of diagnosis and so have had to behaviourally manage the risk of 
hypoglycaemia from that time, There is no association between duration of 
diagnosis and the Worry Subscale, which indicates that worry about 
hypoglycaemia does not significantly lessen or increase over time. 
4. 5. 3. Medication 
The risk of hypoglycaemia associated with different diabetes medications was 
predicted to effect HFS scores, with those patients taking insulin and 
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sulphonylureas predicted to have greater fear than those on metformin or diet 
only. The results indicate that there is a hierarchy of fear according to action of 
medication. Participants on insulin showed the greatest mean HFS scores, 
followed by sulphonylureas and lastly there was little difference between 
metformin and diet only. This was consistent with the results from comparing 
participants that can experience hypoglycaemia compared to those that cannot. 
However, three participants that should not be able to experience hypoglycaemia 
did have a fear of hypoglycaemia. It seems possible that patients can develop a 
fear of hypoglycaemia vicariously. Misinformation or experiences of 
hypoglycaemia from friends, family, other diabetics and the media may all 
provide situations where a fear can develop in someone that cannot experience 
hypoglycaemia. It is also possible that some people may have misunderstood the 
HFS questionnaire. 
4. 5. 4. Anxiety and depression 
Anxiety and depression were predicted to have a positive effect on fear of 
hypoglycaemia. The results show that anxiety has moderate to large correlation 
with HFS scores, especially with the worry subscale, and anxiety is the factor that 
loads highest on fear of hypoglycaemia in multivariate analysis. This result 
indicates the close relationship between fear of hypoglycaemia and other anxiety 
traits. It seems likely that patients who develop a high fear of hypoglycaemia may 
have a predisposition towards anxiety. Depression has a moderate correlation 
with the HFS, and this is not surprising considering there is a correlation between 
the anxiety and depression subscale of the RADS. 
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4. 5. 5. Living alone 
Patients that lived alone were predicted to score more highly on the HFS, 
however, this was not supported by the results. Participants who lived alone were 
no more likely to have a fear of hypoglycaemia than those that were not living 
alone. This was surprising as this group has a greater risk of complications from 
severe hypoglycaemia such as coma, particularly at night as there is no one else 
present to help them manage a severe hypoglycaemic episode. 
4. 5. 6. Ethnicity 
Whether ethnicity would have an influence on HFS scores was unpredicted by the 
model of fear of hypoglycaemia. There did appear to be differences in HFS 
scores for different ethnic groups, however, they were unable to be analysed 
statistically due to small sample sizes. The results are reported because they 
indicate that there may be differences between ethnic groups that could be 
investigated further. Maori had lower average scores on the Behaviour Subscale 
than participants of European descent. If this is a significant difference it could 
place Maori at greater risk of experiencing hypoglycaemia. However, Maori and 
participants of European decent had similar Worry Subscale scores. Pacific Island 
participants' average score fell between that of Maori and those of European 
descent but the average Worry score was lower than both of the other groups. 
These results suggest that there may be differences between these groups in the 
prevalence and presentation of fear of hypoglycaemia. 
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4.5. 7. Age 
Age was another variable that did not have a predicted effect on fear of 
hypoglycaemia. Results show that age is negatively correlated with scores on the 
HFS when type 1 and type 2 diabetes are analysed together, however this is an 
artefact of diagnosis as when type 1 and 2 results are analysed separately there is 
no relationship between age and HFS scores. 
4.5.8. Sex 
Females scored higher on all measures of the HFS except for the Behaviour 
Subscale in participants with typel. Females generally score more highly on 
anxiety measures than males. Females may also have better self-care behaviours 
and therefore may score more highly on Behaviour Subscale. However, there was 
no difference between males and females with type 1 diabetes on the Behaviour 
Subscale, possibly due to needing to manage their blood glucose levels more 
closely than participants with type 2 diabetes. Although sex had an unpredicted 
effect on HFS scores the results indicate that females score more highly on 
average than males. 
In summary the factors that have the strongest relationship with fear of 
hypoglycaemia as measured by the HFS are previous experience and severity of 
hypoglycaemia, type 1 diabetes and general anxiety. Factors that have a smaller 
positive relationship are medications that can cause hypoglycaemia (insulin and 
sulphonylureas), depression, and being female. Factors that have no or mixed 
effects are age, duration of diagnosis, and living alone. Fear of hypoglycaemia 
may be different for different ethnicities, however this is still unclear. 
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4.6. Metabolic control and fear of hypoglycaemia 
Metabolic control was predicted to be associated with a high fear of 
hypoglycaemia. Overall most participants ( 68%) had undesirable metabolic 
control (HbA1c greater than 7mmolL"1) and had an increased risk of developing 
hyperglycaemia related complications. Participants with type 1 diabetes had a 
higher average HbA1c than participants with type 2 diabetes, however the 
difference was small and not likely to be clinically useful. Almost all participants 
had a blood-testing machine and therefore could monitor blood glucose levels 
regularly if they chose to do so. 
Results show that HbA1c is only correlated with scores on the HFS when both 
diagnoses are combined. However, participants with good control scored 
significantly lower on HFS subscales than those with fair and poor control. This 
result suggests that there is a link between fear of hypoglycaemia and higher 
blood glucose levels; however, fear of hypoglycaemia may influence HbA1c in 
some but not all patients. There are many other factors that can influence 
metabolic control as previously discussed. 
4. 7 Treatment of fear of hypoglycaemia suggested by the results of this study 
The results of this study suggest the following approaches may be helpful to the 
treatment of people with a high fear of hypoglycaemia: 
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• Education - diabetes consultants already commonly provide education about 
hypoglycaemia management and the risks associated with hyperglycaemia. 
However, patients with an inappropriate fear of hypoglycaemia may need a 
greater emphasis on education about these topics. It is also important to recognise 
that some patients that cannot experience hypoglycaemia were found to have a 
high fear of hypoglycaemia and this indicates that such information needs to be 
given to patients regardless of their diabetes treatment. 
• The significant relationship between fear of hypoglycaemia and anxiety in 
general indicates that at least some patients with a high fear of hypoglycaemia are 
likely to have other problems with anxiety. It is possible that a general approach 
to anxiety management may be useful when treating these patients. 
• Given that almost 1 in 5 patients of the participants in this study had a high 
fear of hypoglycaemia it seems likely that treatment directed at fear of 
hypoglycaemia specifically may be helpful for at least some of this group, and 
may be beneficial to metabolic control. 
4.8. Future research 
All of the previous studies investigating fear of hypoglycaemia have used a cross 
sectional design. In order to develop and test the theories about the causes of fear 
of hypoglycaemia a longitudinal design may be useful. This would enable 
causation to be investigated. 
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Better measures of glycaemic control need to be employed. Regular blood 
glucose testing at intervals throughout the day may be more helpful and give a 
more realistic indication of daily fluctuations and the risks to individuals of 
hypoglycaemia. 
Anxiety in this study was measured by the HADS, which indicates the level of 
anxiety over the previous week. It is possible that anxiety about attending the 
appointment at the diabetes centre, or other life stressors may have resulted in 
elevated anxiety scores on this instrument. Future studies could investigate 
anxiety with measures that are more reflective of trait anxiety to limit these 
effects. 
Diabetes complications were not investigated in this study. However, it may be 
useful in future studies to record the level of hyperglycaemic related 
complications in people with a fear of hypoglycaemia and compare it to those 
without fear of hypoglycaemia in order to investigate a link between fear of 
hypoglycaemia and increased diabetes related complications as predicted by the 
model presented. 
4.9. Conclusion 
Fear of hypoglycaemia was found to be a reasonably common phenomenon in 
patients attending the Christchurch Diabetes Centre. People with a high fear of 
hypoglycaemia were more likely to score highly on the anxiety subscale of the 
HADS. This suggests that people who develop a fear of hypoglycaemia are more 
anxious in general than those that do not develop a fear of hypoglycaemia. 
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Environmental factors such as previous experience of hypoglycaemia, either 
directly or vicariously, can trigger this underlying vulnerability. Fear of 
hypoglycaemia may result in poor metabolic control in some patients, however, 
there are many other factors that also influence metabolic control and more 
research is needed in this area. 
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APPENDIX A 
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Manaaki tatou • Caring for everyone 
Fear of Low Blood Sugar (Hypoglycaemia) in People who attend the 
Christchurch Diabetes Centre 
Information Sheet 
You are invited to take part in a study to find out how many people who attend the 
Christchurch Diabetes Centre have a fear of low blood sugar (hypoglycaemia or hypo). 
We want to see if fear of low blood sugar is related to medication, type of diabetes, 
diabetes control or mood. All people who attend a clinic appointment at the Diabetes 
Centre between November 2000 and February 2001 will be invited to take part. 
When you attend your clinic appointment you will be asked if you are willing to take part 
in the study. The study involves completing two short questionnaires. The first looks at 
how much people worry about low blood sugars (hypo's) and what they do to avoid 
them. The second asks about mood and anxiety. You do not have to answer any 
questions you do not wish to. Your clinic notes will also be viewed and the HbA 1c blood 
test from that appointment will be recorded. This study is part of an Otago University 
Christchurch School of Medicine Summer Studentship. This study has received ethical 
approval from the Canterbury Ethics Committee. 
Your participation is entirely voluntary (your choice). If you decide to participate, you may 
withdraw at any time without having to give a reason and this will not affect your future 
health care. You do not have to take part in this study, and if you choose not to take part 
you will receive your usual care. If you do agree to take part you will be given two 
questionnaires to complete while you wait for your appointment. The questionnaires 
take between 10 to 20 minutes to complete. You will also be asked the names of your 
diabetes medication (if you take any). You can bring a support person to help you fill out 
the questionnaires. If you have any queries or concerns about your rights as a 
participant in this study you may wish to contact a health and Disability Advocate, 
telephone (03) 377 7501 or 0800377 766 (outside Christchurch). 
You will be asked if you want your questionnaire results and a summary of all results. 
You will also be asked if you are happy for your GP to be sent the results of your 
questionnaire. There may be a delay between you completing the questionnaires and 
the results being available. All questionnaires will be kept in a locked filing cabinet. No 
material which could personally identify you will be used in any reports on this study. 
Please feel free to contact the researcher if you have any questions about this study. 
Joss Tennent 
Senior Clinical Psychologist 
Lead Investigator 
September 2000 
. Diabetes Centre 
Corner Oxford Terrace & Antigua Street, Private Bag 4710, Christchurch, N.Z. 





Manaaki tatou • Caring for everyone 
Fear of Low Blood Sugar (Hypoglycaemia) in People who attend the 
Christchurch Diabetes Centre 
Consent Form 
I have read and I understand the information sheet dated September 2000 for volunteers 
taking part in the study designed to assess how common fear of low blood sugar 
(hypoglycaemia) is in people who attend the Christchurch Diabetes Centre. I have had 
the opportunity to discuss this study. I am satisfied with the answers I have peen given. 
I understand that taking part in this study is voluntary (my choice) and that I may 
withdraw from the study at any time and this will in no way affect my continuing health 
care. 
I understand that my participation in this study is confidential and that no material which 
could identify me will be used in any reports on this study. 
I have had time to consider whether to take part. I know whom to contact if I have any 
side effects to the study. 
I give permission for my GP to be sent a copy of my results 
I wish to receive a copy of my questionnaire results 














Corner Oxford Terrace & Antigua Street, Private Bag 4710, Christchurch, N.Z. 
Telephone: (03) 364 0860 Fax: (03) 364 0171 
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APPENDIXB 
Demographic and diabetes questions 
Hospital Anxiety and Depression Scale 
Hypoglycaemia Fear Survey 
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The following are some general questions about you and your diabetes. 
When was your diabetes first diagnosed? 
What medication are you prescribed for your diabetes? 
When did you last change your diabetes medications? 
Are you currently taking medication for anxiety, low mood or depression? ...... Yes ....... No 
If yes, what is the medication? 
Have you ever done anything to prevent a hypo? ..................... . Yes No 
Have you ever had any symptoms that you thought may be a hypo (low blood sugar)? 
Yes No 
If you have not had a hypo yourself, what do you think might happen if you did? 
Have you ever had a hypo where someone needed to help you manage it? .... Yes · No 
Have you got a blood glucose machine for testing your blood sugars? .......... Yes No 
Do you live alone? ............ · ................................................................... Yes No 
What ethnic group do you identify with? (Please tick) 
D Maori 
D NZ European/Pakeha 
D Pacific Island --------• Other -----------
Hospital-Anxiety and 
Depression Scale (HADS) NFER-NELSON INP'OftMING YOUlli DECISIONS 
Name: __________________ _ Date: 
Clinicians are aware that emotions play an important part in most illnesses. If your 
clinician knows about these feelings he or she will be able to help you more. 
This questionnaire is designed to help your clinician to know how you feel. Read each 
item below and underline the reply which comes closest to how you have been feeling 
in the past week. Ignore the numbers printed at the edge of the questionnaire. 
Don't take too long over your replies, your immediate reaction to each item will 
probably be more accurate than a long, thought-out response. 
I feel tense or 'wound up' 
Most of the time 
A lot of the time 
From time to time, occasionally 
Not at all 
I still enjoy the things I used to enjoy 
Definitely as much 
Not quite so much 
Only a little 
Hardly at all 
I get a sort of frightened feeling as if 
something awful is about to happen 
Very definitely and quite badly 
Yes, but not too badly 
A little, but it doesn't worry me 
Not at all 
I can laugh and see the funny side of things 
As much as I always could 
Not quite so much now 
Definitely not so much now 
Not at all · 
Worrying thoughts go through my mind 
A great deal of the time 
A lot of the time 
Not too often 
Very little 




Most of the time 




Not at all 
I feel as if I am slowed down 
Nearly all the time 
Very oftel). 
Sometimes 
Not at all 
I get a sort of frightened feeling like 
'butterflies' in the stomach 




I have lost interest in my appearance 
Definitely 
I don't take as much care as I should 
I may not take quite .as much care 
I take just as much care as ever 
I feel restless as if I have to be on 
the move 
Very much indeed 
Quite a lot 
Not very much 
Not at all 
I look forward with enjoyment to things 
As much as I ever did 
Rather less than I used to 
Definitely less than I used to 
Hardly at all 
I get sudden feelings of panic 
Very often indeed 
Quite often 
Not very often 
Not at all 






Now check that you have answered all the questions 
TOTAL 
This form is printed in green. Any other colour is an unauthorized photocopy. 
HADS copyright ©R.P. Snaith and A.S. Zigmond, 1983, 1992, 1994. 
Record form items originally published inAct:a Psychiat:rica Scandinavica 67, 361-70, copyright ©Munksgaard International 
Publishers Ltd, Copenhagen, 1983. 
This edition first published in 1994 by The NFER-NELSON Pu_blishing Company Ltd, Darville House, 2 Oxford Road East, 
Windsor, Berkshire SL4 IDF, UK. All rights reserved. 
Code 4460 01 4 Printed in Great Britain 1(6.94) 
81 
11. Worry Below is a list of concerns people with diabetes sometimes have. Please 
read each item carefully (do not skip any). Circle one of the numbers to the right 
that best describes how often you worry about each item because of low blood 
sugar. 
Never · Rarely Sometimes Often Always 
I worry about. .. 
11. Not recognising / realising I 0 1 2 3 4 
am having a low blood sugar 
12. Not having food, fruit, or juice 0 1 2 3 4 
with me 
13. Passing out in public 0 1 2 3 4 
14. Embarrassing myself or my 0 1 2 3 4 
friends in a social situation 
15. Having a reaction (hypo / low 0 1 2 3 4 
blood sugar) while alone 
16. Appearing stupid or drunk 0 1 2 3 4 
17. Losing control 0 1 2 3 4 
18. No one being around to help 0 1 2 3 4 
me during a reaction (hypo / 
low blood sugar) 
19. Having a reaction (hypo / low 0 1 2 3 4 
blood sugar) while driving 
20. Making a mistake or having 0 1 2 3 4 
an accident 
21. Getting a bad evaluation or 0 1 2 3 4 
being criticised 
22. Difficulty thinking clearly 0 1 2 ·3 4 
when responsible for others 
23. Feeling light-headed or dizzy 0 1 2 3 4 
This part of the survey may or may not apply to you. If particular questions 
do not apply to you, circle the "Never" answer. 
Low Blood Sugar Survey 
I. Behaviour: Below is a list of things people with diabetes do in order to avoid low 
blood sugar. Read each item carefully. Circle one of the numbers to the right that 
best describes what you do during your daily routine to AVOID low blood sugar. 
Never Rarely Sometimes Often Always 
1. I eat large snacks at bedtime 0 1 2 3 4 
2. I avoid being alone when my 0 1 2 3 4 
blood sugar is likely to be low 
3. If I test my blood sugars, I 0 1 2 3 4 
keep them a little high to be 
on the safe side 
4. I keep my blood sugars high 0 1 2 3 4 
when I will be alone for a 
while 
5. I eat or drink something as 0 1 2 3 4 
soon as I feel the first sign of 
low blood sugar 
6. I reduce my insulin when I 0 1 2 3 4 
think my blood sugar is low 
7. I keep my blood sugar high 0 1 2 3 4 
when I plan to be in a long 
meeting or at a party 
8. I carry fast-acting sugar with 0 1 2 3 4 
me 
9. I avoid exercise when I think 0 1 2 3 4 
my blood sugar is low 
10 I check my blood sugar often 0 1 2 3 4 
when I plan to be in a long 
meeting or out to a party 
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